All In MedTech

FDA Clearance Tracker · P130014-S022

Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 15, 2026

Approved

Time to decision

209 days

Received Dec 18, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130014-S022
Device name
Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant
Applicant location
Freiburg
Received
Dec 18, 2025
Decided
Jul 15, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130014

Device type

Device class
Class III

Every decision under product code NQR

FDA's approval statement

As written in FDA's record.

The Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant are indicated for use in patients who are 13 years of age and older, as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure during cranial and spinal procedures.

Source documents

Other decisions for Stryker Leibinger GmbH & Co KG

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.